Left atrial dimension and cardiovascular outcomes in patients with and without atrial fibrillation: a systematic review and meta-analysis.


Journal

Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087

Informations de publication

Date de publication:
12 2019
Historique:
received: 04 04 2019
revised: 15 07 2019
accepted: 24 07 2019
pubmed: 20 8 2019
medline: 13 6 2020
entrez: 19 8 2019
Statut: ppublish

Résumé

The prognostic value of left atrial (LA) dimensions may differ between patients with and without atrial fibrillation (AF). MEDLINE and EMBASE were searched for studies that investigated the association between LA echocardiographic parameters measured by transthoracic echocardiography and cardiovascular outcomes in patients with or without AF. Data were independently abstracted by two reviewers and pooled using random-effects meta-analysis. The primary outcome was incident stroke or thromboembolic events. Secondary outcomes were heart failure, all-cause mortality and major adverse cardiac events (MACE). Twenty-three studies of patients with AF (14 939 patients) and 68 studies of patients without AF (50 720 patients) in this systematic review. Increasing LA diameter was significantly associated with stroke and thromboembolic events in patients without AF (risk ratio (RR) 1.38, 95% CI 1.02 to 1.87; p=0.03), but not in patients with AF (RR 1.02, 95% CI 0.98 to 1.07; p=0.27; p for difference=0.05). Increasing LA diameter index was significantly associated with MACE in patients with AF (RR 1.13, 95% CI 1.09 to 1.17; p<0.001) and in patients without AF (RR 2.98, 95% CI 1.90 to 4.66; p<0.001), with stronger effects in non-AF populations (p for difference <0.001). Greater LA volume index was significantly associated with the risk of MACE in patients with AF (RR 1.01, 95% CI 1.00 to 1.02; p=0.03) and in non-AF populations (RR 1.08, 95% CI 1.05 to 1.10; p<0.001), the association being stronger in individuals without AF (p for difference <0.001). Larger LA parameters were associated with various adverse cardiovascular events. Many of these associations were stronger in individuals without AF, highlighting the potential importance of LA myopathy.

Identifiants

pubmed: 31422362
pii: heartjnl-2019-315174
doi: 10.1136/heartjnl-2019-315174
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1884-1891

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Lorin Froehlich (L)

Division of Cardiology, Department of Medicine, University Hospital Basel, Basel, Switzerland.
Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland.

Pascal Meyre (P)

Division of Cardiology, Department of Medicine, University Hospital Basel, Basel, Switzerland.
Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland.

Stefanie Aeschbacher (S)

Division of Cardiology, Department of Medicine, University Hospital Basel, Basel, Switzerland.
Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland.

Steffen Blum (S)

Division of Cardiology, Department of Medicine, University Hospital Basel, Basel, Switzerland.
Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland.

Daniela Djokic (D)

Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland.

Michael Kuehne (M)

Division of Cardiology, Department of Medicine, University Hospital Basel, Basel, Switzerland.
Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland.

Stefan Osswald (S)

Division of Cardiology, Department of Medicine, University Hospital Basel, Basel, Switzerland.
Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland.

Beat A Kaufmann (BA)

Division of Cardiology, Department of Medicine, University Hospital Basel, Basel, Switzerland.
Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland.

David Conen (D)

Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland conend@mcmaster.ca.
Population Health Research Institute, Hamilton, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH